Albumin Excipient Market Report 2026

Albumin Excipient Market Overview

• Albumin Excipient market size has reached to $5.15 billion in 2025 • Expected to grow to $7.15 billion in 2030 at a compound annual growth rate (CAGR) of 6.9% • Growth Driver: Chronic Disease Rise Fuels Albumin Excipient Market Growth • Market Trend: Innovative Strategic Partnership Propel Market Growth • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Albumin Excipient Market?

Albumin excipient is a type of protein that is found in blood. An excipient is an inactive ingredient that serves as a carrier or stabilizer for the active pharmaceutical ingredient. The main product types of albumin excipients are human serum albumin and recombinant albumin. Human Serum albumin is the primary protein made by the liver and is present in the human plasma. These are used by various end-users such as the pharmaceutical and biotechnology industry, research institutes, and others.

What Is The Albumin Excipient Market Growth Forecast?

The albumin excipient market size is expected to see strong growth in the next few years. It will grow to $7.15 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to expansion of biopharmaceutical sector, technological advancements in protein excipients, rising prevalence of chronic diseases, growth in contract manufacturing, increasing regulatory approvals for novel drug formulations. Major trends in the forecast period include protein stabilization innovations, excipient formulation advancements, enhanced drug delivery systems, regulatory compliance and gmp adoption, supply chain optimization.

Global Albumin Excipient Market Segmentation

1) By Product: Human Serum Albumin, Recombinant Albumin 2) By End-Users: Pharmaceutical And Biotechnology Industry, Research Institutes, Other End Users 3) By Application Type: Injectable Formulations, Vaccine Formulations, Cell Culture Or Bioprocessing, Diagnostic Formulations Subsegments: 1) By Human Serum Albumin: 5% Human Serum Albumin, 20% Human Serum Albumin 2) By Recombinant Albumin: Recombinant Human Serum Albumin, Recombinant Bovine Serum Albumin

What Is The Driver Of The Albumin Excipient Market?

The rising prevalence of chronic diseases is expected to propel the growth of the albumin excipient market going forward. A chronic disease is a form of illness that lasts three months or more and can deteriorate with time. Albumin is used as a blood volumizer and is the most abundant circulating protein in plasma. It acts as a versatile protein carrier for drug targeting and for improving the pharmacokinetic profile of peptide or protein-based drugs is involved in the treatment of various diseases, including cancer and diabetes. For instance, in February 2024, according to the World Health Organization, a Switzerland-based agency of the United Nations, it is projected that over 35 million new cancer cases will arise by 2050, marking a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the rising prevalence of chronic diseases is driving the growth of the albumin excipient industry.

Key Players In The Global Albumin Excipient Market

Major companies operating in the albumin excipient market are Albumin Therapeutics LLC, Biotest AG, CSL Behring, Grifols S.A., InVitria Inc., Octapharma AG, Kedrion Biopharma, LFB USA Inc., Baxter International Inc., Merck KGaA, Albumedix A/S, Bio Products Laboratory Ltd., Ventria Bioscience Inc., Novartis AG, China Biologic Products Holdings Inc., ProMetic Life Sciences Inc., Sanquin, Takeda Pharmaceutical Company Limited, FUJIFILM Irvine Scientific Inc., Shire Plc, Biopharma, Hualan Biological Engineering Inc., Shanghai RAAS Blood Products Co. Ltd.

Global Albumin Excipient Market Trends and Insights

Major companies operating in the albumin excipient market are adopting a strategic partnership approach to provide essential biotechnology and pharmaceutical sectors. Strategic partnerships refer to a process in which companies leverage each other's strengths and resources to achieve mutual benefits and success. For instance, in October 2023, ARTES Biotechnology GmbH is Germany-based biotechnology company partnered with Basic Pharma is a Netherlands-based pharmaceutical company, to advance recombinant protein production. With this partnership, they aim to advance pharmaceutical recombinant protein production by streamlining the supply chain and reducing time-to-market for new products.

What Are Latest Mergers And Acquisitions In The Albumin Excipient Market?

In November 2025, Evonik, a Germany-based specialty chemicals company, partnered with InVitria to expand access to animal-free human serum albumin for biopharma innovation. Through this partnership, Evonik aims to strengthen its Precision Biosolutions portfolio by providing safer and more consistent albumin excipients that support improved process efficiency and product stability. InVitria is a US-based biopharmaceutical company specializing in the development and manufacture of recombinant human serum albumin (rHSA) excipient.

Regional Insights

North America was the largest region in the Albumin Excipient market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global albumin excipient market report during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Albumin Excipient Market?

The albumin excipient market consists of sales of ovalbumin, and bovine serum albumin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Albumin Excipient Market Report 2026?

The albumin excipient market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the albumin excipient industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.